116 filings
Page 4 of 6
8-K
qnb6g6
28 Apr 20
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
4:50pm
8-K
759ti5
31 Mar 20
Other Events
4:08pm
8-K
ua2zfkk 8tlb
26 Feb 20
CRISPR Therapeutics Proposes Changes to the Board of Directors
4:10pm
8-K
g66lblxzyuqy08h
12 Feb 20
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
4:05pm
8-K
c6brqqhe j15
29 Jan 20
Departure of Directors or Certain Officers
4:16pm
8-K
ztea1isd zaugk
27 Dec 19
Termination of a Material Definitive Agreement
4:06pm
8-K
f89u jrvxj
16 Dec 19
Entry into a Material Definitive Agreement
7:01am
8-K
7u9ncm1 r6m
22 Nov 19
Crispr Therapeutics Announces Proposed Public Offering of Common Shares
4:02pm
8-K
2r2gx p1ynjcxiqs9v
19 Nov 19
Regulation FD Disclosure
8:21am
8-K
yuvh16d2q9xra1
28 Oct 19
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
7:05am
8-K
j7firip kh
30 Aug 19
Entry into a Material Definitive Agreement
4:10pm
8-K
4fcem
29 Jul 19
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results
4:05pm
8-K
secu6r
26 Jun 19
Other Events
8:45am
8-K
q941l citte1hq4pz
13 Jun 19
Departure of Directors or Certain Officers
4:44pm
8-K
g1md1k97qvdwsfm
6 Jun 19
Entry into a Material Definitive Agreement
5:20pm
8-K
g6h204ak191a0c e9vv
29 Apr 19
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results
4:05pm
8-K
zjrjzt1rwp0sl
25 Feb 19
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001
8:16am
8-K
y3uk2umjwus22f8p
25 Feb 19
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
8:15am
8-K
fbheiojnj1ff5
9 Nov 18
Other Events
12:00am
8-K
45ruw129bzvf63i24hj
7 Nov 18
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results
5:22pm